Hepatitis B vaccines (Q35621657)

9 August 2017

1 reference

title

Hepatitis B vaccines (English)

1 reference

9 August 2017

1 reference

Daniel Shouval

1

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

Journal of Hepatology

1 reference

9 August 2017

39 Suppl 1

1 reference

9 August 2017

S70-6

1 reference

The molecular biology of the hepatitis B viruses

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Molecular virology and pathogenesis of hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Molecular epidemiology of hepatitis B virus vaccine variants in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Hepatitis B virus contains pre-S gene-encoded domains

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Protective potential of hepatitis B virus antigens other than the S gene protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Immunochemical structure of the hepatitis B surface antigen vaccine--II. Analysis of antibody responses in human sera against the envelope proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Pre-S1 antigens and antibodies early in the course of acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Development and production aspects of a recombinant yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Cost-effectiveness of prenatal screening and immunization for hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

The first combined vaccine against hepatitis A and B: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Genetic prediction of nonresponse to hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

T- and B-cell recognition of hepatitis B viral antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Clinical relevance of hepatitis B viral mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

A common-source outbreak of fulminant hepatitis B in a hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Overview of biological effects of addition of DNA molecules to cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

A biphasic pattern of anti-pre-S responses in acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

Assay of preS epitopes and preS1 antibody in hepatitis B virus carriers and immune persons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900152-1

7 January 2021

10.1016/S0168-8278(03)00152-1

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14708681